Earlier in October, Pfizer Inc (NYSE ... On the other hand, Moderna Inc (NASDAQ: MRNA) posted a surprise profit and higher ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

Moderna says Health Canada has approved its mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and ...

There is no evidence Japan has named the COVID-19 vaccine the “most deadly drug in history,” as the post claims.

the mRNA vaccines from Pfizer and Moderna — aren’t effective. Get top local stories in DFW delivered to you every morning.

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Pfizer-BioNTech: The Pfizer-BioNTech vaccine ... performing almost as well as the mRNA vaccines in their early trials. The FDA authorized an updated COVID vaccine from Novavax at the end of ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...